



UNIVERSITÀ DI PARMA

ARCHIVIO DELLA RICERCA

University of Parma Research Repository

Enhanced photosensitizing properties of protein bound curcumin

This is a pre print version of the following article:

Original

Enhanced photosensitizing properties of protein bound curcumin / Cozzolino, Marco; Delcanale, Pietro; Montali, Chiara; Tognolini, Massimiliano; Giorgio, Carmine; Corrado, Miriam; Cavanna, Luigi; Bianchini, Paolo; Diaspro, Alberto; Abbruzzetti, Stefania; Viappiani, Cristiano. - In: LIFE SCIENCES. - ISSN 0024-3205. - (2019), p. 116710. [10.1016/j.lfs.2019.116710]

Availability:

This version is available at: 11381/2861704 since: 2021-10-22T22:05:47Z

Publisher:

Elsevier Inc.

Published

DOI:10.1016/j.lfs.2019.116710

Terms of use:

Anyone can freely access the full text of works made available as "Open Access". Works made available

Publisher copyright

note finali coverpage

(Article begins on next page)

1 **Enhanced photosensitizing properties of protein bound curcumin**

2

3 Marco Cozzolino^{1,2,3,&}, Pietro Delcanale^{4,&}, Chiara Montali⁵, Massimiliano Tognolini*⁶, Carmine
4 Giorgio⁶, Miriam Corrado⁶, Luigi Cavanna⁷, Paolo Bianchini^{1,2}, Alberto Diaspro^{1,2,3}, Stefania
5 Abbruzzetti*⁵, Cristiano Viappiani⁵

6

7 ¹Nanoscopy, Istituto Italiano di Tecnologia, via Morego 30, Genoa 16163, Italy

8 ²Nikon Imaging Center, Istituto Italiano di Tecnologia, via Morego 30, Genoa 16163, Italy

9 ³ Department of Physics, University of Genoa, via Dodecaneso 33, Genoa 16146, Italy.

10 ⁴ Institute for Bioengineering of Catalonia (IBEC), the Barcelona Institute of Science and
11 Technology (BIST), Barcelona, Spain

12 ⁵ Dipartimento di Scienze Matematiche, Fisiche e Informatiche, Università di Parma, Parco area
13 delle Scienze 7/A, 43124 Parma, Italy

14 ⁶ Dipartimento di Scienze degli Alimenti e del Farmaco, Università di Parma, Parco area delle
15 Scienze 27/A, 43124 Parma, Italy

16 ⁷ Dipartimento di oncologia-ematologia. Azienda USL di Piacenza. Via Taverna, 49, 29121 Piacenza,
17 Italy

18 & These authors contributed equally to this work.

19 *Corresponding authors:

20 Stefania Abbruzzetti Dipartimento di Scienze Matematiche, Fisiche e Informatiche, Università di
21 Parma, Parco area delle Scienze 7/A, 43124 Parma, Italy, email: stefania.abbruzzetti@unipr.it

22 Massimiliano Tognolini Dipartimento di Scienze degli Alimenti e del Farmaco, Università di Parma,
23 Parco area delle Scienze 27/A, 43124 Parma, Italy email: massimiliano.tognolini@unipr.it

24

25

26

27 **Abstract**

28 The naturally occurring compound curcumin has been proposed for a number of pharmacological
29 applications. In spite of the promising chemotherapeutic properties of the molecule, the use of
30 curcumin has been largely limited by its chemical instability in water. In this work, we propose the
31 use of water soluble proteins to overcome this issues in perspective applications to photodynamic
32 therapy of tumors. Bovine serum albumin binds curcumin with moderate affinity and solubilizes
33 the hydrophobic compound preserving its photophysical properties for several hours. Cell viability
34 assays demonstrate that when bound to serum albumin, curcumin is an effective photosensitizer
35 for HeLa cells, with better performance than curcumin alone. Confocal fluorescence imaging reveals
36 that when curcumin is delivered alone, it preferentially associates with mitochondria, whereas
37 curcumin bound to bovine serum albumin is found in additional locations within the cell, a fact that
38 may be related to the higher phototoxicity observed in this case. The higher bioavailability of the
39 photosensitizing compound curcumin when bound to serum albumin may be exploited to increase
40 the efficiency of the drug in photodynamic therapy of tumors.

41

42

- 43 List of Abbreviations
- 44 apoMb, apomyoglobin
- 45 BSA, Bovine Serum Albumin
- 46 DMSO, dimethyl sulfoxide
- 47 FWHM, full width at half maximum
- 48 HSA, Human Serum Albumin
- 49 Hyp, Hypericin
- 50 LED, light emitting diode
- 51 Mb, Horse heart myoglobin
- 52 MTT, Dimethyl thiazolyl diphenyl tetrazolium
- 53 PBS, Phosphate Buffered Saline
- 54 PDT, photodynamic therapy
- 55 PS, photosensitizer
- 56

57 **Introduction**

58 Curcumin is a naturally-occurring pigment found in the root turmeric or *Curcuma longa*. Turmeric
59 is a wide-spread spice, typical of Indian cooking, that also found use in traditional Indian and
60 Chinese medicine. Curcumin is the main responsible for the yellow/orange color of this spice and it
61 is widely studied for its therapeutic potential in the treatment of a large number of diseases. [1]

62 Curcumin has been used in traditional medicine for the treatment of several respiratory disorders
63 and certain tumors. [2, 3] The compound is reported to modulate a variety of signaling molecules.
64 [4] Although a number of preclinical and clinical studies have indicated the chemotherapeutic
65 potential of curcumin, also in cancer, [5-7] its use remains controversial. Neither curcumin nor
66 curcumin derivatives appear to possess the properties required for a good drug candidate since
67 they have poor chemical stability, low water solubility, low absorption from the gut, high intestinal
68 degradation, fast metabolism and rapid plasma elimination, finally resulting in poor bioavailability
69 and low toxicity (it was “generally recognized as safe” by FDA). [8]

70 Curcumin is a relatively hydrophobic molecule, readily soluble in organic solvents like ethanol,
71 methanol, or DMSO. Its photophysical properties are strongly dependent on the characteristics of
72 the solvent (polarity, H-bond donating or accepting properties, and pH). Curcumin usually displays
73 an absorption band around 420 nm and a large Stokes shift, with fluorescence emission in the 450-
74 550 nm region of the spectrum. [9] The decay of the excited state preferentially occurs with non-
75 radiative processes, mainly related to an inter- or intra-molecular proton transfer. As a
76 consequence, fluorescence emission is characterized by a relatively low quantum yield (usually
77 lower than 0.1) and a short lifetime (a few hundred ps). [10] Inter-system crossing also occurs with
78 low yield, leading to a triplet state that can be quenched by molecular oxygen. [9, 11]

79 Curcumin is one of the most exploited photosensitizers for antibacterial photosensitization-based
80 treatment (aPDT), [12-14] especially for the treatments of oral diseases. [15] Its use has indeed

81 several advantages like ready availability, low cost, efficacy against several kinds of micro-
82 organisms and negligible dark toxicity (curcumin is pharmacologically safe at a dose of 8 g/day).
83 [10]

84 Despite its wide-spread use as photosensitizer in photodynamic therapy (PDT), the mechanisms of
85 curcumin's photo-toxicity are quite unclear. Both singlet oxygen and superoxide anion are known
86 to be photo-generated by energy and charge transfer processes, respectively. [16-19] Despite
87 showing oxygen-dependent photo-toxicity, curcumin is also known to be an antioxidant and even
88 a singlet oxygen quencher under certain conditions. [20, 21] Thus, curcumin's photo-reactivity
89 appears to be strongly dependent on the environment and it is likely that several mechanisms, such
90 as photo-generation of different ROS and other photo-products, contribute to its overall photo-
91 toxicity in a biological system. [18]

92 A crucial issue regarding the use of curcumin for PDT applications is the stability of the molecule in
93 aqueous environments. [8] Curcumin is indeed known to rapidly degrade in aqueous buffers at
94 alkaline or physiological pH. [22-24] Photo-degradation also occurs, particularly under irradiation
95 with UV light. [25, 26] It is thus convenient, if not necessary, to combine the photosensitizer with a
96 delivery vehicle in order to increase its stability and its water-solubility. Plasma proteins like
97 albumins or fibrinogen, [8, 27-29] liposomes, [29] micelles, [30] nanoparticles [31] and
98 cyclodextrins [32] are some examples of systems used to stabilize the molecule in aqueous
99 solutions.

100 In this work, we explore the capability of two water-soluble proteins, apomyoglobin (apoMb) and
101 bovine serum albumin (BSA), to act as delivery systems for curcumin. We show that when curcumin
102 is bound to either protein, it becomes more stable. The enhancement in stability is particularly
103 relevant in the case of BSA, which is able to stabilize curcumin for hours, long enough to achieve a
104 high and reproducible phototoxic effect when used to treat cultured tumor cells. We have

105 previously demonstrated that both proteins are very effective in transporting the naturally
106 occurring photosensitizer hypericin (Hyp), and allow to obtain highly bioavailable photosensitizing
107 compounds for PDT of tumors [33] and aPDT against, e.g., *Staphylococcus aureus*. [34-36] Hyp-
108 apoMb proved very effective also when tumor spheroids of HeLa cells were treated. [33] Water
109 soluble proteins may thus represent interesting delivery means to minimize drug degradation and
110 loss in herbal medicine, and to increase drug bioavailability and accumulation in tissues to be
111 treated. [37]

112

113

114 **Materials and Methods**

115 Horse heart myoglobin (Mb), bovine serum albumin (BSA), and curcumin were from Sigma-Aldrich.
116 Apomyoglobin (apoMb) was prepared from myoglobin by acid acetone extraction, using standard
117 biochemical procedures. [38, 39] Phosphate Buffered Saline (PBS) was prepared as 0.2g/l KCl, 8.0g/l
118 NaCl, 0.2g/l KH₂PO₄, 1.65g/l Na₂HPO₄, pH 7.4.

119

120 **Molecular docking**

121 Formation of the ApoMb-curcumin and BSA-curcumin complexes was modelled by SwissDock
122 (<http://www.swissdock.ch/>), a web service that predicts the molecular interactions that may occur
123 between a target protein and a small molecule. [40, 41] Target structures for BSA and apoMb were
124 PDB code 3v03 and PDB code 1bvc, respectively. The representative best pose was selected in both
125 cases.

126

127 **Cell cultures**

128 All culture media and supplements were purchased from Euroclone. Dimethyl thiazolyl diphenyl
129 tetrazolium (MTT) was purchased from Applichem. Cells were maintained in a humidified
130 atmosphere of 95% air, 5% CO₂ at 37°C.

131 Curcumin was delivered to the cell cultures using two different protocols. Concentrated stock
132 solutions in ethanol were then diluted to the desired concentrations either in the presence of
133 apoMb or BSA. Attempts to deliver curcumin as a PBS buffered solution resulted in lower
134 phototoxicity and scattered results, due to instability of the compound in these conditions.

135

136 **Viability assay.**

137 MTT was used to evaluate HeLa viability as previously described. [33] Cells were seeded in 96-well
138 cell culture plates at the density of 3×10^5 cells/ml, the following day they were starved and treated
139 with increasing concentrations of curcumin either conjugated with apoMb or not, or control (1.2%
140 ethanol for curcumin). Curcumin was manipulated in the dark. Cells were exposed to light 30
141 minutes after treatment with the compound and incubated for 24 hours in standard conditions,
142 without light exposure. MTT was finally added at the concentration of 1 mg/ml and incubated for
143 2 hours. The resulting formazan crystals were solubilized with DMSO and the absorbance was
144 measured at 550 nm using an ELISA plate reader (Sunrise, TECAN, Switzerland).

145

146 **Irradiation of cultured cells.**

147 Cells were irradiated using a LED light source (LED par 64 short, Show Tec (Highlite International
148 B.V., Kerkrade, The Netherlands) for which the blue output at 460 nm (30 nm FWHM, 30.7 mW/cm²)
149 was selected.

150 The irradiance was homogeneous on the whole surface of a 96 well plate. Exposure of cultured cells
151 was performed for 0, 2, 3, and 5 minutes, corresponding to light fluences of 0, 3.6, 5.5, and 9.2
152 J/cm², respectively.

153

154 **Fluorescence microscopy**

155 Spinning disk confocal microscopy allows high-speed three-dimensional imaging of living cells; it
156 utilizes multiple pinholes that project a series of simultaneously excitation light beams onto the
157 specimen in a multiplexed pattern, that is subsequently detected from a camera after fluorescence
158 emission has passed through the same pinholes. Since such a parallelization requires a low laser
159 power intensity at the specimen to excite fluorescence, photobleaching and phototoxicity are
160 minimized. The microscope is composed of a TiE inverted Microscope, four laser sources (405nm,
161 488nm, 561nm, 640nm) and a Yokogawa CSU-X1 spinning disk confocal head, which comprises two
162 disks of about 20,000 pinholes and the relative microlenses. The fluorescence light is collected by
163 an Andor EMCCD camera, Ixon3 897.


164

165

166 **Results and discussion**

167

168 Curcumin is unstable in water and its spectral properties undergo major changes within minutes
169 from preparation of the solutions. Immediately after preparing a solution in PBS buffer, the
170 compound shows a prominent absorbance band at 420 nm and a very weak (almost negligible),
171 structure-less fluorescence emission (black curves in **Figures 1A** and **1B**). **Figures 1A** and **1B** also
172 show the changes observed in the absorption and fluorescence emission spectra of curcumin in PBS
173 buffer at selected delays after dilution from a concentrated ethanol solution. **Panel C** reports the
174 kinetics of changes in the absorption spectrum monitored at 420 nm over the first 20 minutes. On
175 the contrary, ethanol solutions of curcumin show much stronger absorption and fluorescence
176 emission (cyan curves in **Figures 1A** and **B**), and their spectral properties are stable over days.
177 The spectral instability observed in PBS solutions poses strong limitations to applications in PDT of
178 tumors and in antibacterial photosensitization-based treatment.
179 Oxidation of the compound may be prevented, or at least made less efficient, if a delivery agent is
180 used to solubilize curcumin in water. Among available carriers, we have decided to test a few water
181 soluble proteins endowed with hydrophobic cavities, that proved to be efficient carriers with other
182 hydrophobic photosensitizers. Specifically, we selected apoMb and BSA, that were found capable
183 of transporting hypericin and other hydrophobic dyes. [34-36]



184

185


186 **Figure 1.** Absorption (**panel A**) and fluorescence emission spectra (**panel B**) of curcumin (12 μM) in
 187 PBS buffer at pH = 7.4, collected at increasing delays after dilution from a concentrated ethanol
 188 solution (black, 0 min; red, 10 min; green, 20 min; blue, 90 min). For comparison, the cyan curves
 189 represent the absorption (panel A) and fluorescence emission (panel B, on a /10 scale) from
 190 curcumin in ethanol at the same concentration. **Panel C.** Progress curve (blue curve) for changes in
 191 Fluorescence emission. The red solid curve is the result of a fit with a single exponential decay
 192 model, with lifetime 7 ± 1 min. $T = 20$ °C.

193

194 ApoMb was found to bind curcumin, although with quite low affinity. ApoMb is endowed with a
195 rather large hydrophobic cavity, normally hosting the heme in the holoprotein. In the presence of
196 apoMb, the absorption spectrum of curcumin undergoes changes in shape and the fluorescence
197 emission of curcumin increases with increasing apoMb concentration, indicating binding of the
198 compound to the protein with a relatively low association constant ($K_a \sim 10^3 \text{ M}^{-1}$).

199

200 The stability of absorption and fluorescence emission spectra of curcumin is significantly improved
201 when bound to apoMb in PBS at pH 7.4 (**Figures 2A** and **2B**), resulting in a much slower (~ 25-fold)
202 degradation of the spectral properties.



203

204 **Figure 2.** Absorption (**panel A**) and fluorescence emission spectra (**panel B**) of curcumin (2 μM)
 205 bound to apoMb (55 μM) in PBS pH = 7.4, at selected increasing delays (black 0 min, red 40 min,
 206 green 130 min) after preparation of the complex. Absorption (**panel C**) and fluorescence emission
 207 spectra (**panel D**) of curcumin (3 μM) bound to BSA (30 μM) in PBS pH = 7.4, at selected increasing
 208 delays (black 0 min, red 290 min) after preparation of the complex. **Panel E** compares the
 209 normalized absorbance at 420 nm after dilution/preparation of the complex at increasing delays
 210 for curcumin in PBS (black circles), curcumin (2 μM) bound to apoMb (55 μM) in PBS pH = 7.4 (red
 211 circles), and curcumin (3 μM) bound to BSA (30 μM) in PBS pH = 7.4 (green circles). All experiments

212 were conducted at 20 °C. Black solid lines are the fits with a single exponential decay. The retrieved
213 lifetimes are 5 ± 1 min for curcumin in water and 130 ± 10 min for curcumin bound to apoMb. No
214 change was appreciable for curcumin bound to BSA in the investigated time window (5 hours).

215


216 A slightly stronger binding was observed for BSA ($\sim 5\times 10^4$ M⁻¹). A similar value was obtained also for
217 HSA, for which an association constant of 6.1×10^4 M⁻¹ was reported. [29] **Figures 2C** and **2D**
218 demonstrate that when bound to BSA, the spectral properties of curcumin are stable over at least
219 5 hours, which corresponds to a dramatic increase in stability (lifetime ≥ 1000 s) also in comparison
220 to the complex with apoMb.

221 A previous investigation reported curcumin stabilization by HSA already at low protein
222 concentration (roughly 13 μ M). The rate of degradation under those conditions was found to be
223 reduced only by tenfold, [27], much less than the effect reported in Figure 2, possibly due to the
224 lower protein concentration employed in that work.

225 The increased stability of curcumin in the presence of apoMb or BSA is considered to arise from the
226 protection against hydrolysis provided to the compound by the macromolecule scaffold. The
227 hydrophobic pocket, which is occupied by the heme in the holoprotein myoglobin, in principle
228 provides a suitable binding site for curcumin. Similarly, BSA is endowed with several docking sites
229 for hydrophobic compounds, which could potentially host curcumin. A qualitative estimate of the
230 theoretical feasibility of fitting curcumin into the hydrophobic cavities of apoMb or BSA was
231 assessed through the computational macromolecular docking software Swissdock
232 (www.swissdock.ch/). **Figure 3 A** shows the lowest energy pose for curcumin bound to the heme
233 cavity in apoMb. Other binding sites are present on the protein, but their energy scores appear
234 more unfavorable. The existence of other binding sites on myoglobin was suggested also by

235 previous experimental investigations. [42] **Figure 3 B** reports the lowest energy pose for curcumin
236 bound to BSA.

237 The superior stability of curcumin spectral properties when bound to BSA suggests that this delivery
238 system may be safely and reliably employed in photodynamic investigations. We have therefore
239 performed cell viability assays after having treated cultured cells with curcumin-BSA and exposed
240 them to blue light.



241

242 **Figure 3.** Best poses for curcumin bound to apoMb (PDB code 1wr) and BSA (PDB code 3v03) as
243 determined by Swissdock (<http://www.swissdock.ch/>).


244

245 **Phototoxicity of curcumin-BSA**

246

247 Cell viability of HeLa cells in the presence of curcumin or curcumin-BSA was determined as a
248 function of PS concentration and illumination time, i.e. light fluence. The plots (**Figure 4**) evidence

249 a clear concentration-dependent cytotoxic effect, with can be observed at all irradiation times (2,
 250 3 and 5 minutes) when cells are treated with either curcumin or curcumin-BSA.
 251 When curcumin-BSA is used, phototoxicity is observed at lower concentrations as reported in
 252 **Figure 4B** for 2 min illumination. Under these conditions, the concentration at which a 50%
 253 reduction in cell viability is observed is about 3-times lower when curcumin-BSA is used in
 254 comparison with curcumin. Increasing light-exposure time to 5 minutes decreases the difference in
 255 cytotoxicity for curcumin and curcumin-BSA. The lower phototoxicity observed when curcumin is
 256 delivered without BSA may correlate with the instability of curcumin in PBS solutions discussed
 257 above.



258
 259 **Figure 4.** Cell viability for HeLa cells incubated with curcumin or curcumin-BSA and exposed to blue
 260 light. **Panel A.** Concentration-dependence (curcumin at 0.1, 0.3, 1, and 3 μM) and time-response
 261 (exposure for 0, 2, 3 and 5 minutes) for viability of HeLa cells treated with increasing concentrations
 262 of curcumin-BSA (dark bars) or curcumin (light bars) and exposed to increasing illumination times.
 263 Data are the means of at least three independent experiments. BSA was 30 μM. Viability controls
 264 were collected for cells grown in PBS, in the presence of 0.6% EtOH, in the presence of 30 μM BSA.
 265 **Panel B.** dose response for viability of HeLa cells treated with increasing curcumin (yellow) or
 266 curcumin-BSA (orange) concentrations for 2-minute illumination with blue light.

267

268 **Cellular uptake is different for curcumin and curcumin-BSA**


269 Taking advantage of the bright fluorescence emission of curcumin it is possible to follow the uptake
270 of the compound by cells. When curcumin is delivered to cultured cells using a concentrated
271 ethanol solution, fluorescence is observed from inside the cellular structures after just a few
272 minutes of incubation. **Figure 5 (A-C)** shows that fluorescence emission from curcumin co-localizes
273 with the fluorescence emission from MitoTracker red. Thus, accumulation of curcumin when
274 delivered without a carrier appears to occur at the mitochondria, as previously reported. [43, 44]
275 Curcumin and curcumin derivatives targeting mitochondria exhibited significant cytotoxicity
276 towards several cancer cell lines, inducing significant ROS generation, cell-cycle arrest and
277 apoptosis. [45]

278 **Figure 5 (D-F)** shows that when HeLa cells are incubated with curcumin-BSA, the observed
279 distribution of the compound appears quite different from that observed for curcumin alone.
280 Diffuse fluorescence from curcumin is observed in large areas of the cytoplasm, in addition to
281 mitochondria. The more distributed loading of the cell appears to be a direct consequence of the
282 higher bioavailability of the photoactive compound when delivered bound to BSA. The lack of
283 aggregation and the dramatically increased stability of curcumin bound to BSA mean that the
284 compound is bioavailable at higher concentration and for longer times, so that uptake from cells is
285 more extensive. In the presence of HeLa cells, we expect that fully photoactive curcumin is
286 efficiently transferred to the cell structures by the carrier protein, due to the higher affinity of the
287 compound for lipids and possibly for other macromolecules endowed with hydrophobic binding
288 sites. The process we envision for curcumin-BSA is similar to the one we recently demonstrated for
289 the self-assembled hypericin-apomyoglobin construct. [33] In that case, the rapid and efficient
290 transfer of monomeric apoMb-bound Hyp to the plasma membrane was found to speed up cell
291 loading in comparison to the case when Hyp is added to the solution without the protein carrier.

292 Admittedly, the high affinity for membranes of the hydrophobic PS transported by the protein, held
293 in place by non-covalent interactions, may limit the bioavailability of the photosensitizing
294 compounds in systemic applications. Such applications have not yet been attempted.

295 Although the details of the uptake mechanism are beyond the scope of the present work, the wider
296 distribution of the photoactive compound may be responsible for the more extensive damage
297 induced by illumination of HeLa cells treated with curcumin-BSA.

298



299

300 **Figure 5.** Fast confocal spinning disk fluorescence imaging of HeLa cells incubated 15 min with
301 mitoTracker Deep red [0.3 μ M], and 10 min with curcumin [15 μ M] (**A-C**) or curcumin-BSA (**D-F**). A,
302 D green channel (curcumin); B, E red channel (mitoTracker); C, F composite. Curcumin channel:
303 excitation 405 nm, emission 460/60, exposure time 50 ms. MitoTracker channel: excitation 633 nm,
304 emission 700/75 nm, exposure time 200 ms. For all the images the pixels area is 512x512, and pixel
305 size is 0.16 μ m. Scale bar 10 μ m.

306

307 **Conclusions**

308 The use of proteins, capable of binding curcumin with moderate affinity, allows to stabilize the
309 photosensitizer and make it possible to use the compound in model studies without the interfering
310 complications of its chemical degradation. In particular, when BSA is used as a delivery vehicle, the
311 efficiency in reduction of cell viability upon illumination becomes substantially higher.

312 Delivery of curcumin with BSA has an impact on the intracellular distribution of the compound.
313 When delivered without the protein carrier, curcumin is mainly localized in the mitochondria. On
314 the other hand, when curcumin is bound to BSA, the cellular distribution appears more
315 homogeneous, likely associated with a variety of target structures.

316 The above properties lead to higher phototoxicity of curcumin-BSA in comparison to curcumin
317 alone, a fact that may be exploited to overcome the known limitations of this photosensitizing
318 compound.

319

320 **Acknowledgements**

321 LC, CV and SA acknowledge support from Azienda USL di Piacenza, Italy, and Fondazione di
322 Piacenza e Vigevano.

323

324 **Competing Interests**

325 The authors declare that no competing interest exists.

326

327 **References**

328

329 [1] B.B. Aggarwal, B. Sung, Pharmacological basis for the role of curcumin in chronic diseases: an age-old
330 spice with modern targets, Trends in Pharmacological Sciences 30(2) (2009) 85-94.

331 [2] L.L. Miguel, Anticancer and carcinogenic properties of curcumin: Considerations for its clinical
332 development as a cancer chemopreventive and chemotherapeutic agent, Molecular Nutrition & Food
333 Research 52(1) (2008) S103-S127.

334 [3] A. Goel, B.B. Aggarwal, Curcumin, the Golden Spice From Indian Saffron, Is a Chemosensitizer and
335 Radiosensitizer for Tumors and Chemoprotector and Radioprotector for Normal Organs, Nutrition and Cancer
336 62(7) (2010) 919-930.

337 [4] S.C. Gupta, S. Patchva, B.B. Aggarwal, Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials,
338 The AAPS Journal 15(1) (2013) 195-218.

339 [5] P. Anand, C. Sundaram, S. Jhurani, A.B. Kunnumakkara, B.B. Aggarwal, Curcumin and cancer: An "old-age";
340 disease with an "age-old" solution, Cancer Lett. 267(1) (2008) 133-164.

341 [6] S. Nobili, D. Lippi, E. Witort, M. Donnini, L. Bausi, E. Mini, S. Capaccioli, Natural compounds for cancer
342 treatment and prevention, Pharmacological Research 59(6) (2009) 365-378.

343 [7] H. Batra, S. Pawar, D. Bahl, Curcumin in combination with anti-cancer drugs: A nanomedicine review,
344 Pharmacological Research 139 (2019) 91-105.

345 [8] K.M. Nelson, J.L. Dahlin, J. Bisson, J. Graham, G.F. Pauli, M.A. Walters, The Essential Medicinal Chemistry
346 of Curcumin, J. Med. Chem. 60(5) (2017) 1620-1637.

347 [9] M.K. Sujata, K.I. Priyadarsini, K.P. Dipak, M. Tulsi, Effect of Solvent on the Excited state Photophysical
348 Properties of Curcumin, Photochem. Photobiol. 72(5) (2000) 625-631.

349 [10] K.I. Priyadarsini, Photophysics, photochemistry and photobiology of curcumin: Studies from organic
350 solutions, bio-mimetics and living cells, Journal of Photochemistry and Photobiology C: Photochemistry
351 Reviews 10(2) (2009) 81-95.

352 [11] T. Qian, L. Kun, B. Gao, R. Zhu, X. Wu, S. Wang, Photo-ionization and photo-excitation of curcumin
353 investigated by laser flash photolysis, *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*
354 116 (2013) 6-12.

355 [12] M. Glueck, B. Schamberger, P. Eckl, K. Plaetzer, New horizons in microbiological food safety:
356 Photodynamic Decontamination based on a curcumin derivative, *Photochemical & Photobiological Sciences*
357 16(12) (2017) 1784-1791.

358 [13] N. Tortik, P. Steinbacher, T. Maisch, A. Spaeth, K. Plaetzer, A comparative study on the antibacterial
359 photodynamic efficiency of a curcumin derivative and a formulation on a porcine skin model, *Photochemical*
360 *& Photobiological Sciences* 15(2) (2016) 187-195.

361 [14] S. Winter, N. Tortik, A. Kubin, B. Krammer, K. Plaetzer, Back to the roots: photodynamic inactivation of
362 bacteria based on water-soluble curcumin bound to polyvinylpyrrolidone as a photosensitizer,
363 *Photochemical & Photobiological Sciences* 12(10) (2014) 1795-1802.

364 [15] C. Santezi, B.D. Reina, L.N. Dovigo, Curcumin-mediated Photodynamic Therapy for the treatment of oral
365 infections; A review, *Photodiagnosis Photodyn. Ther.* 21 (2018) 409-415.

366 [16] L. Shen, H.-F. Ji, H.-Y. Zhang, A TD-DFT study on triplet excited-state properties of curcumin and its
367 implications in elucidating the photosensitizing mechanisms of the pigment, *Chem. Phys. Lett.* 409(4) (2005)
368 300-303.

369 [17] L. Shen, H.-Y. Zhang, H.-F. Ji, Successful Application of TD-DFT in Transient Absorption Spectra
370 Assignment, *Org. Lett.* 7(2) (2005) 243-246.

371 [18] F.C. Colin, B. Piotr, J.R. Krzysztof, G.M. Ann, H.S. Robert, A.D. Thomas, Spectral and photochemical
372 properties of curcumin, *Photochem. Photobiol.* 59(3) (1994) 295-302.

373 [19] A.A. Gorman, I. Hamblett, V.S. Srinivasan, P.D. Wood, Curcumin derived transients: a pulsed laser and
374 pulse radiolysis study, *Photochem. Photobiol.* 59(4) (1994) 389-398.

375 [20] T. Masuda, K. Hidaka, A. Shinohara, T. Maekawa, Y. Takeda, H. Yamaguchi, Chemical Studies on
376 Antioxidant Mechanism of Curcuminoid: Analysis of Radical Reaction Products from Curcumin, *Journal of*
377 *Agricultural and Food Chemistry* 47(1) (1999) 71-77.

378 [21] K.C. Das, C.K. Das, Curcumin (diferuloylmethane), a singlet oxygen (1O_2) quencher, *Bioch. Bioph. Res.*
379 *Com.* 295(1) (2002) 62-66.

380 [22] L.C. Price, R.W. Buescher, Kinetics of Alkaline Degradation of the Food Pigments Curcumin and
381 Curcuminoids, *Journal of Food Science* 62(2) (1997) 267-269.

382 [23] Y.-J. Wang, M.-H. Pan, A.-L. Cheng, L.-I. Lin, Y.-S. Ho, C.-Y. Hsieh, J.-K. Lin, Stability of curcumin in buffer
383 solutions and characterization of its degradation products, *Journal of Pharmaceutical and Biomedical Analysis*
384 15(12) (1997) 1867-1876.

385 [24] H. Tønnesen, J. Karlsen, Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in
386 aqueous solution., *Z Lebensm Unters Forsch* 180 (1985) 402-404.

387 [25] A. Khurana, C.T.L. Ho, High-performance liquid chromatographic analysis of curcuminoids and their
388 photo-oxidative decomposition compounds in *Curcuma longa*, *J. Liq. Chromatogr.* 11 (1988) 2295-2304.

389 [26] M.J. Ansari, S. Ahmad, K. Kohli, J. Ali, R.K. Khar, Stability-indicating HPTLC determination of curcumin in
390 bulk drug and pharmaceutical formulations, *Journal of Pharmaceutical and Biomedical Analysis* 39(1) (2005)
391 132-138.

392 [27] M.H.M. Leung, T.W. Kee, Effective Stabilization of Curcumin by Association to Plasma Proteins: Human
393 Serum Albumin and Fibrinogen, *Langmuir* 25(10) (2009) 5773-5777.

394 [28] A. Barik, K.I. Priyadarsini, M. Hari, Photophysical Studies on Binding of Curcumin to Bovine Serum
395 Albumin, *Photochem. Photobiol.* 77(6) (2003) 597-603.

396 [29] A. Kunwar, A. Barik, R. Pandey, K.I. Priyadarsini, Transport of liposomal and albumin loaded curcumin to
397 living cells: An absorption and fluorescence spectroscopic study, *BBA - General Subjects* 1760(10) (2006)
398 1513-1520.

399 [30] M.H.M. Leung, H. Colangelo, T.W. Kee, Encapsulation of Curcumin in Cationic Micelles Suppresses
400 Alkaline Hydrolysis, *Langmuir* 24(11) (2008) 5672-5675.

401 [31] C. Mohanty, S.K. Sahoo, The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an
402 aqueous nanoparticulate formulation, *Biomaterials* 31(25) (2010) 6597-6611.

403 [32] H.H. Tønnesen, M. Masson, T. Loftsson, Studies of curcumin and curcuminoids. XXVII. Cyclodextrin
404 complexation: solubility, chemical and photochemical stability, *Int. J. Pharm.* 244(1) (2002) 127-135.

405 [33] P. Bianchini, M. Cozzolino, M. Oneto, L. Pesce, F. Pennacchietti, M. Tognolini, C. Giorgio, S. Nonell, L.
406 Cavanna, P. Delcanale, S. Abbruzzetti, A. Diaspro, C. Viappiani, Hypericin - apomyoglobin an enhanced
407 photosensitizer complex for the treatment of tumour cells, *Biomacromolecules* 20(5) (2019) 2024–2033.

408 [34] D. Pezzuoli, M. Cozzolino, C. Montali, L. Brancaleon, P. Bianchini, M. Zantedeschi, S. Bonardi, C. Viappiani,
409 S. Abbruzzetti, Serum albumins are efficient delivery systems for the photosensitizer hypericin in
410 photosensitization-based treatments against *Staphylococcus aureus*, *Food Control* 94 (2018) 254-262.

411 [35] P. Delcanale, F. Pennacchietti, G. Maestrini, B. Rodríguez-Amigo, P. Bianchini, A. Diaspro, A. Iagatti, B.
412 Patrizi, P. Foggi, M. Agut, S. Nonell, S. Abbruzzetti, C. Viappiani, Subdiffraction localization of a
413 nanostructured photosensitizer in bacterial cells, *Sci. Rep.* 5 (2015) 15564.

414 [36] J. Comas-Barceló, B. Rodríguez-Amigo, S. Abbruzzetti, P.d. Rey-Puech, M. Agut, S. Nonell, C. Viappiani, A
415 self-assembled nanostructured material with photosensitising properties, *RSC Advances* 3 (2013) 17874-
416 17879.

417 [37] V. Devi, N. Jain, K. Valli, Importance of novel drug delivery systems in herbal medicines, *Pharmacognosy*
418 *Reviews* 4(7) (2010) 27-31.

419 [38] A. RossiFanelli, E. Antonini, A. Caputo, Studies on the structure of hemoglobin. I. Physicochemical
420 properties of human globin, *Biochim. Biophys. Acta* 30 (1958) 608-615.

421 [39] S. Abbruzzetti, E. Crema, L. Masino, A. Vecli, C. Viappiani, J.R. Small, L.J. Libertini, E.W. Small, Fast events
422 in protein folding. Structural volume changes accompanying the early events in the N->I transition of
423 apomyoglobin induced by ultrafast pH jump, *Biophys. J.* 78(1) (2000) 405-415.

424 [40] A. Grosdidier, V. Zoete, O. Michielin, Fast docking using the CHARMM force field with EADock DSS, *J.*
425 *Comput. Chem.* 32(10) (2011) 2149-2159.

426 [41] A. Grosdidier, O. Michielin, V. Zoete, SwissDock, a protein-small molecule docking web service based on
427 EADock DSS, *Nucleic Acids Research* 39(suppl_2) (2011) W270-W277.

428 [42] S. Mondal, S. Ghosh, Effect of curcumin on the binding of cationic, anionic and nonionic surfactants with
429 myoglobin, *J. Mol. Struct.* 1134 (2017) 292-297.

430 [43] S. Ben-Zichri, S. Kolusheva, M. Danilenko, S. Ossikbayeva, W.J. Stabbert, J.L. Poggio, D.E. Stein, Z.
431 Orynbayeva, R. Jelinek, Cardiolipin mediates curcumin interactions with mitochondrial membranes,
432 *Biochimica et Biophysica Acta (BBA) - Biomembranes* 1861(1) (2019) 75-82.

433 [44] A. Moustapha, P.A. Pérétout, N.E. Rainey, F. Sureau, M. Geze, J.M. Petit, E. Dewailly, C. Slomianny, P.X.
434 Petit, Curcumin induces crosstalk between autophagy and apoptosis mediated by calcium release from the
435 endoplasmic reticulum, lysosomal destabilization and mitochondrial events, *Cell Death Discovery* 1 (2015)
436 15017.

437 [45] C.A. Reddy, V. Somepalli, T. Golakoti, A.K. Kanugula, S. Karnewar, K. Rajendiran, N. Vasagiri, S. Prabhakar,
438 P. Kuppusamy, S. Kotamraju, V.K. Kutala, Mitochondrial-Targeted Curcuminoids: A Strategy to Enhance
439 Bioavailability and Anticancer Efficacy of Curcumin, *PLOS ONE* 9(3) (2014) e89351.

440